Sign In

Andrew W. Lam, PharmD

Investor in life.

Andrew W. Lam, PharmD, is a prominent figure in the biotech and private equity sectors, currently serving as the Managing Director and Head of Biotech Private Equity at Ally Bridge Group. He is also a Board Member at Endeavor Biomedicines. Based in New York, Lam has extensive experience in the pharmaceutical and biotechnology industries, focusing on investments and strategic development.

In his role at Ally Bridge, he has been involved in various initiatives and collaborations aimed at advancing healthcare solutions. His professional background includes significant contributions to the field of drug development and commercialization, particularly in oncology and antibody-drug conjugates.123

Lam holds a Doctor of Pharmacy (PharmD) degree, which complements his expertise in both clinical and business aspects of the pharmaceutical industry. His leadership and strategic insights are recognized within the biotech community, making him a key player in shaping the future of biomedicine.12

Highlights

Sep 5 · linkedin

Thanks, Cure., for the shoutout. It's exciting to see how fast the Life Sciences Sherpas community has scaled in #NYC since 2021. Extremely appreciative of all the support from our sponsors and engagement by our members in our mission to help accelerate life science innovation through increase connectivity within the ecosystem. We are looking forward to expanding in #Boston, #SanFrancisco and #SanDiego within the next year. #lifesciences #biotech #dealmakers

Life Sciences Sherpas is a volunteer-organized collective that aims to foster life sciences collaboration by improving stakeholder connectivity. We do this by bringing together folks within life sciences hubs to invitation-only, sponsored networking events intended to nurture professional connections and deal-making. Our members are “C-suite and adjacent” – that is, C-suite executives in decision-making capacities or related participants, such as public equity and private equity investors, business development executives of strategic acquirers, and other stakeholders (e.g. investment bankers, equity research analysts and outside counsel). Our NYC chapter has grown to become the largest platform-neutral executive-level life sciences network since it was established in 2021.

Aug 16 · linkedin

Congratulations to Boston University School of Law-grad and lawyer-turned Ally Bridge Group biotech investor Paresh Kumar, PharmD, JD for being recognized in Best Lawyers’ 2025 Ones to Watch list!

Related Questions

What is Andrew W. Lam's role at Ally Bridge Group?
How did Andrew W. Lam transition from pharmacy to biotech private equity?
What are some notable projects Andrew W. Lam has worked on at Ally Bridge Group?
How has Andrew W. Lam's career evolved over the years?
What are Andrew W. Lam's key achievements in the biotech industry?
Andrew W. Lam, PharmD
Andrew W. Lam, PharmD, photo 1
Andrew W. Lam, PharmD, photo 2
Add to my network

Location

New York, New York, United States